Oncogenic protein tyrosine kinases

[1]  Piero Musiani,et al.  Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. , 2004, Cancer research.

[2]  M. Campiglio,et al.  Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (‘Iressa’) is independent of EGFR expression level , 2004, Journal of cellular physiology.

[3]  D. Larsimont,et al.  Evaluation of HER-2/NEU Protein Expression in Breast Cancer by Immunohistochemistry: An Interlaboratory Study Assessing the Reproducibility of HER-2/NEU Testing , 2002, Breast Cancer Research and Treatment.

[4]  O. Nanni,et al.  Prognostic significance of biologic markers in node-negative breast cancer patients: a prospective study , 2000, Breast Cancer Research and Treatment.

[5]  F. Kern,et al.  MCF-7 breast cancer cells overexpressing transfectedc-erbB-2 have anin vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivityin vivo , 1995, Breast Cancer Research and Treatment.

[6]  A. Ullrich,et al.  Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic , 1991, Journal of Clinical Immunology.

[7]  S. Eccles,et al.  Differential modulation of proliferation, matrix metalloproteinase expression and invasion of human head and neck squamous carcinoma cells by c-erbB ligands , 2004, Clinical & Experimental Metastasis.

[8]  M. Campiglio,et al.  Role of HER2 in wound-induced breast carcinoma proliferation , 2003, The Lancet.

[9]  G. Sala,et al.  Feedback inhibition by RALT controls signal output by the ErbB network , 2003, Oncogene.

[10]  J. Kim,et al.  The Role of ErbB2 Signaling in the Onset of Terminal Differentiation of Oligodendrocytes In Vivo , 2003, The Journal of Neuroscience.

[11]  M. Campiglio,et al.  Role of proliferation in HER2 status predicted response to doxorubicin , 2003, International journal of cancer.

[12]  D. Stern,et al.  Neural and mammary gland defects in ErbB4 knockout mice genetically rescued from embryonic lethality , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Gottfried Konecny,et al.  Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. , 2003, Journal of the National Cancer Institute.

[14]  Barbara L. Smith,et al.  Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  H. Kato,et al.  Correlation between encoded protein overexpression and copy number of the HER2 gene with survival in non‐small cell lung cancer , 2003, International journal of cancer.

[16]  P. Ohashi,et al.  Making and breaking tolerance. , 2002, Current opinion in immunology.

[17]  S. Ménard,et al.  Prevention of spontaneous mammary adenocarcinoma in HER‐2/neu transgenic mice by foreign DNA , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  Thomas Dittmar,et al.  Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of c‐erbB‐2 receptor via epidermal growth factor receptor , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[19]  M. Bui,et al.  Prognostic and predictive value of HER2/neu oncogene in breast cancer , 2002, Microscopy research and technique.

[20]  Jayanta Debnath,et al.  The Role of Apoptosis in Creating and Maintaining Luminal Space within Normal and Oncogene-Expressing Mammary Acini , 2002, Cell.

[21]  Anthony Rhodes,et al.  Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries. , 2002, American journal of clinical pathology.

[22]  M. Wolter,et al.  Gene amplification and protein overexpression of c-erb-b2 in Barrett carcinoma and its precursor lesions. , 2002, American journal of clinical pathology.

[23]  M. Raffeld,et al.  Her-2/neu expression and gene amplification in gastrinomas: correlations with tumor biology, growth, and aggressiveness. , 2002, Cancer research.

[24]  N. Tsavaris,et al.  Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes , 2002, British Journal of Cancer.

[25]  Guido Forni,et al.  Antitumor vaccines: is it possible to prevent a tumor? , 2002, Cancer Immunology, Immunotherapy.

[26]  Carmen Birchmeier,et al.  Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Peter A Kaufman,et al.  Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. , 2002, Journal of the National Cancer Institute.

[28]  Greg Yothers,et al.  Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience. , 2002, Journal of the National Cancer Institute.

[29]  M. Hung,et al.  Novel targets of Akt, p21(Cipl/WAF1), and MDM2. , 2002, Seminars in oncology.

[30]  T. Foy,et al.  Designing HER2 vaccines. , 2002, Seminars in oncology.

[31]  Hermann Herbst,et al.  Common Adult Stem Cells in the Human Breast Give Rise to Glandular and Myoepithelial Cell Lineages: A New Cell Biological Concept , 2002, Laboratory Investigation.

[32]  J. Beneke,et al.  HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays. , 2002, American journal of clinical pathology.

[33]  M. Cheever,et al.  Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  F. Hirsch,et al.  Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas , 2002, British Journal of Cancer.

[35]  D. Larsimont,et al.  HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  G. Forni,et al.  Prophylactic cancer vaccines. , 2002, Current opinion in immunology.

[37]  D. Jäger,et al.  Clinical cancer vaccine trials. , 2002, Current opinion in immunology.

[38]  Lei Xu,et al.  Tumour biology: Herceptin acts as an anti-angiogenic cocktail , 2002, Nature.

[39]  F. Hirsch,et al.  Epidermal growth factor receptor family in lung cancer and premalignancy. , 2002, Seminars in oncology.

[40]  Lyndsay N Harris,et al.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  M. Campiglio,et al.  HER-2-positive breast carcinomas as a particular subset with peculiar clinical behaviors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  Benjamin D. Smith,et al.  Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[44]  M. Campiglio,et al.  Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[45]  Y. Zeng,et al.  Absence of evidence for HER2 amplification in nasopharyngeal carcinoma. , 2002, Cancer genetics and cytogenetics.

[46]  J. Feldner,et al.  Cancer cell motility--on the road from c-erbB-2 receptor steered signaling to actin reorganization. , 2002, Experimental cell research.

[47]  J. Bartlett,et al.  Gene amplification and overexpression of HER2 in renal cell carcinoma , 2002, BJU international.

[48]  A Choudhury,et al.  Cellular immunity to the Her-2/neu protooncogene. , 2002, Advances in cancer research.

[49]  Piero Musiani,et al.  Combined Allogeneic Tumor Cell Vaccination and Systemic Interleukin 12 Prevents Mammary Carcinogenesis in HER-2/neu Transgenic Mice , 2001, The Journal of experimental medicine.

[50]  Yong Liao,et al.  HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation , 2001, Nature Cell Biology.

[51]  S. Ménard,et al.  HER2 as a Prognostic Factor in Breast Cancer , 2001, Oncology.

[52]  N. Rosen,et al.  The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. , 2001, Cancer research.

[53]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[54]  Y. Yarden.  The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. , 2001, European journal of cancer.

[55]  M. Bissell,et al.  ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini , 2001, Nature Cell Biology.

[56]  T. Benstead,et al.  PROGRESS IN CLINICAL NEUROSCIENCES: Charcot-Marie-Tooth Disease and Related Inherited Peripheral Neuropathies , 2001, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[57]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[58]  P. Musiani,et al.  Inhibition of mammary carcinogenesis by systemic interleukin 12 or p185neu DNA vaccination in Her-2/neu transgenic BALB/c mice. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[59]  A. Ullrich,et al.  The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. , 2001, Endocrine-related cancer.

[60]  K. Knutson,et al.  Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. , 2001, The Journal of clinical investigation.

[61]  S. Ménard,et al.  Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  M. Campiglio,et al.  HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[63]  P. Stanton,et al.  The value of the human epidermal growth factor receptor-2 (HER2) as a prognostic marker. , 2001, European journal of cancer.

[64]  Yosef Yarden,et al.  Molecular mechanisms underlying ErbB2/HER2 action in breast cancer , 2000, Oncogene.

[65]  A. Aderem,et al.  The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[66]  M. Kris,et al.  Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[67]  Piero Musiani,et al.  DNA Vaccination Against Rat Her-2/Neu p185 More Effectively Inhibits Carcinogenesis Than Transplantable Carcinomas in Transgenic BALB/c Mice1 2 , 2000, The Journal of Immunology.

[68]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[69]  P. Triozzi,et al.  Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine. , 2000, Cancer research.

[70]  H. Allgayer,et al.  c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  R. Kerbel,et al.  'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. , 2000, European journal of cancer.

[72]  John M. Daly,et al.  ErbB2 Potentiates Breast Tumor Proliferation through Modulation of p27Kip1-Cdk2 Complex Formation: Receptor Overexpression Does Not Determine Growth Dependency , 2000, Molecular and Cellular Biology.

[73]  R. Stein,et al.  Evolutionary Analysis of the ErbB Receptor and Ligand Families , 2000, Journal of Molecular Evolution.

[74]  A. Sacchi,et al.  Cooperative Signaling between α6β4Integrin and ErbB-2 Receptor Is Required to Promote Phosphatidylinositol 3-Kinase-dependent Invasion* , 2000, The Journal of Biological Chemistry.

[75]  L. Presta,et al.  Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.

[76]  M. Campiglio,et al.  Role of HER2 gene overexpression in breast carcinoma , 2000, Journal of cellular physiology.

[77]  D. Talmage,et al.  Cysteine-Rich Domain Isoforms of the Neuregulin-1 Gene Are Required for Maintenance of Peripheral Synapses , 2000, Neuron.

[78]  S. Eccles,et al.  Cell biology of lymphatic metastasis. The potential role of c-erbB oncogene signalling. , 2000, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[79]  M. Colombo,et al.  Antitumor vaccination: where we stand. , 2000, Haematologica.

[80]  A. Sckell,et al.  Targeting HER‐2/neu for active‐specific immunotherapy in a mouse model of spontaneous breast cancer , 1999, International journal of cancer.

[81]  P. Caroni,et al.  Peripheral nervous system defects in erbB2 mutants following genetic rescue of heart development. , 1999, Genes & development.

[82]  N. Robert,et al.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  M. Sliwkowski,et al.  Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). , 1999, Seminars in oncology.

[84]  Y. Yarden,et al.  The C‐terminus of the kinase‐defective neuregulin receptor ErbB‐3 confers mitogenic superiority and dictates endocytic routing , 1999, The EMBO journal.

[85]  D. Stern,et al.  Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloalveolar development and lactation , 1999, Oncogene.

[86]  Kuo-Fen Lee,et al.  Rescue of the Cardiac Defect in ErbB2 Mutant Mice Reveals Essential Roles of ErbB2 in Peripheral Nervous System Development , 1999, Neuron.

[87]  P. Lollini,et al.  Cytokine gene therapy: hopes and pitfalls. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[88]  L. Esserman,et al.  Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice , 1999, Cancer Immunology, Immunotherapy.

[89]  P. Musiani,et al.  Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin 12. , 1999, Cancer research.

[90]  S. Ménard,et al.  Target molecules for immunotherapy of inflammatory breast carcinomas. , 1998, European journal of cancer.

[91]  M. Freeman,et al.  An Autoregulatory Cascade of EGF Receptor Signaling Patterns the Drosophila Egg , 1998, Cell.

[92]  B Fisher,et al.  erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. , 1998, Journal of the National Cancer Institute.

[93]  D A Berry,et al.  erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. , 1998, Journal of the National Cancer Institute.

[94]  J. Fletcher,et al.  Multivariate analysis of prognostic factors in lymph node negative breast cancer , 1998 .

[95]  R. Derynck,et al.  Activation and function of the epidermal growth factor receptor and erbB-2 during mammary gland morphogenesis. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[96]  D. Riethmacher,et al.  The ErbB2 and ErbB3 receptors and their ligand, neuregulin-1, are essential for development of the sympathetic nervous system. , 1998, Genes & development.

[97]  David C. Lee,et al.  Dynamic expression and activation of ERBB receptors in the developing mouse mammary gland. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[98]  S. Martino,et al.  HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[99]  G. Frantz,et al.  ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2-and heregulin-deficient mice. , 1997, Development.

[100]  S. Ménard,et al.  High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[101]  D. Riethmacher,et al.  Severe neuropathies in mice with targeted mutations in the ErbB3 receptor , 1997, Nature.

[102]  C. Birchmeier,et al.  Isoform-specific expression and function of neuregulin. , 1997, Development.

[103]  D. Slamon,et al.  HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[104]  Dihua Yu,et al.  Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. , 1997, Cancer research.

[105]  M. Cheever,et al.  HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. , 1997, Advances in cancer research.

[106]  M. Miloso,et al.  Post-transcriptional Control Regulates Transforming Growth Factor α in the Human Carcinoma KB Cell Line* , 1996, The Journal of Biological Chemistry.

[107]  M. Campiglio,et al.  Laminin activates the p185HER2 oncoprotein and mediates growth inhibition of breast carcinoma cells. , 1996, British Journal of Cancer.

[108]  Y. Yarden,et al.  A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor , 1996, Molecular and cellular biology.

[109]  W. Muller,et al.  Mutations affecting conserved cysteine residues within the extracellular domain of Neu promote receptor dimerization and activation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[110]  E. Raz,et al.  Immunostimulatory DNA Sequences Necessary for Effective Intradermal Gene Immunization , 1996, Science.

[111]  L. Theill,et al.  Neuregulins with an Ig-like domain are essential for mouse myocardial and neuronal development. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[112]  Y. Yarden,et al.  ErbB‐2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. , 1996, The EMBO journal.

[113]  S. Ménard,et al.  Macrophage infiltrate and prognosis in c-erbB-2-overexpressing breast carcinomas. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[114]  Kuo-Fen Lee,et al.  Requirement for neuregulin receptor erbB2 in neural and cardiac development , 1995, Nature.

[115]  Rüdiger Klein,et al.  Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor , 1995, Nature.

[116]  R. Lupu,et al.  Bidirectional interactions between the estrogen receptor and the c‐erbB‐2 signaling pathways: Heregulin inhibits estrogenic effects in breast cancer cells , 1995, International journal of cancer.

[117]  W. Birchmeier,et al.  Sequential requirement of hepatocyte growth factor and neuregulin in the morphogenesis and differentiation of the mammary gland , 1995, The Journal of cell biology.

[118]  G. Mann,et al.  A mutation in the epidermal growth factor receptor in waved-2 mice has a profound effect on receptor biochemistry that results in impaired lactation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[119]  M. Campiglio,et al.  Colocalization of the p185HER2 oncoprotein and integrin α6β4 in Calu‐3 lung carcinoma cells , 1994 .

[120]  N. Copeland,et al.  The mouse waved-2 phenotype results from a point mutation in the EGF receptor tyrosine kinase. , 1994, Genes & development.

[121]  M. Bissell,et al.  The tumor-promoting effect of wounding: a possible role for TGF-beta-induced stromal alterations. , 1994, Critical reviews in oncogenesis.

[122]  Wei Chen,et al.  Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. , 1994, Cancer research.

[123]  S. Ménard,et al.  Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients. , 1993, Cancer research.

[124]  R. Cardiff,et al.  Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[125]  L. Presta,et al.  Humanization of an anti-p185HER2 antibody for human cancer therapy. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[126]  D. Slamon,et al.  Radiolabeled antibody targeting of the HER-2/neu oncoprotein. , 1992, Cancer research.

[127]  S. Ménard,et al.  Prognostic significance of her‐2/neu expression in breast cancer and its relationship to other prognostic factors , 1991, International journal of cancer.

[128]  M. Kraus,et al.  Oncogenic potential of erbB-2 in human mammary epithelial cells. , 1991, Oncogene.

[129]  A. Ullrich,et al.  Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. , 1991, Growth regulation.

[130]  Paul W. Sternberg,et al.  The let-23 gene necessary for Caenorhabditis elegans vulval induction encodes a tyrosine kinase of the EGF receptor subfamily , 1990, Nature.

[131]  C. Cordon-Cardo,et al.  Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. , 1990, Oncogene.

[132]  A. Ullrich,et al.  Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. , 1990, Cancer research.

[133]  M. Kraus,et al.  Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[134]  E. Scanlon,et al.  The influence of surgical trauma on experimental metastasis , 1989, Cancer.

[135]  A. Ullrich,et al.  p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor , 1989, Molecular and cellular biology.

[136]  C R King,et al.  erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. , 1987, Science.

[137]  P. Seeburg,et al.  Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. , 1985, Science.

[138]  P. Seeburg,et al.  Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells , 1984, Nature.